Loading company
Kala BIO, Inc.
KALA · Nasdaq · ·
$0.51+11.1%Sep 29 close
- 1M
- -26.3%
- 6M
- -94.1%
- 1Y
- -99.3%
- 5Y
- -100.0%
KALA · Nasdaq · ·
$0.51+11.1%Sep 29 close
The quarter ending December 31, 2022, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2022 | 3 months toDec 31, 2021 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $1.9M | -100.00% |
| Profit | -$1.6M | -$11.2M | +85.83% |
| Profit per share | -$0.14 | -$1.93 | +92.75% |
| Free Cash Flow | -$26.2M | -$23.1M | -13.28% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Kala BIO, Inc. has no earnings call transcript available.
“The second quarter of 2025 was a pivotal period for KALA, marked by the completion of patient enrollment in our Phase 2b CHASE trial of KPI-012 in PCED and the continued execution of our clinical and corporate strategy,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
BIO, Inc. KALA is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare and severe diseases of the eye. KALA’s biologics-based investigational therapies utilize KALA’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA is also exploring the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Kala BIO, Inc.’s Item 2.02 8-K filed August 8, 2025; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.